KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Invested Capital (2016 - 2025)

Historic Invested Capital for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $1.1 billion.

  • Supernus Pharmaceuticals' Invested Capital rose 68.05% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 68.05%. This contributed to the annual value of $1.1 billion for FY2024, which is 1124.57% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Invested Capital stood at $1.1 billion for Q3 2025, which was up 68.05% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Invested Capital ranged from a high of $1.3 billion in Q3 2022 and a low of $786.0 million during Q1 2021
  • Moreover, its 5-year median value for Invested Capital was $990.5 million (2023), whereas its average is $1.0 billion.
  • In the last 5 years, Supernus Pharmaceuticals' Invested Capital surged by 5405.62% in 2021 and then crashed by 2428.6% in 2023.
  • Supernus Pharmaceuticals' Invested Capital (Quarter) stood at $1.2 billion in 2021, then decreased by 24.08% to $907.3 million in 2022, then grew by 7.3% to $973.6 million in 2023, then grew by 11.25% to $1.1 billion in 2024, then fell by 2.05% to $1.1 billion in 2025.
  • Its Invested Capital was $1.1 billion in Q3 2025, compared to $1.1 billion in Q2 2025 and $1.1 billion in Q1 2025.